-
1
-
-
0029115531
-
US Renal Transplant Mycophenolate Mofetil Study Group: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
-
Sollinger H.W. US Renal Transplant Mycophenolate Mofetil Study Group: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60 (1995) 225
-
(1995)
Transplantation
, vol.60
, pp. 225
-
-
Sollinger, H.W.1
-
2
-
-
0006986048
-
A blinded, randomized, clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
-
The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group
-
The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized, clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61 (1996) 1029
-
(1996)
Transplantation
, vol.61
, pp. 1029
-
-
-
3
-
-
0034660104
-
Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection
-
Ojo A., Meier-Kriesche H.U., Hanson J.A., et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69 (2000) 2405
-
(2000)
Transplantation
, vol.69
, pp. 2405
-
-
Ojo, A.1
Meier-Kriesche, H.U.2
Hanson, J.A.3
-
4
-
-
0242417526
-
Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration
-
Meier-Kriesche H.U., Steffen B.J., Hochberg A.M., et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 75 (2003) 1341
-
(2003)
Transplantation
, vol.75
, pp. 1341
-
-
Meier-Kriesche, H.U.1
Steffen, B.J.2
Hochberg, A.M.3
-
5
-
-
12144273473
-
Long-term outcomes of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil
-
Hardinger K.L., Brennan D.C., Lowell J., et al. Long-term outcomes of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transplant Int 17 (2004) 609
-
(2004)
Transplant Int
, vol.17
, pp. 609
-
-
Hardinger, K.L.1
Brennan, D.C.2
Lowell, J.3
-
6
-
-
0037663784
-
The impact of mycophenolate dosing patterns on clinical outcomes after renal transplantation
-
Pelletier R.P., Akin B., Henry M.L., et al. The impact of mycophenolate dosing patterns on clinical outcomes after renal transplantation. Clin Transplant 17 (2003) 200
-
(2003)
Clin Transplant
, vol.17
, pp. 200
-
-
Pelletier, R.P.1
Akin, B.2
Henry, M.L.3
-
7
-
-
0042536429
-
Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation
-
Knoll G.A., MacDonald I., Khan A., et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 14 (2003) 2381
-
(2003)
J Am Soc Nephrol
, vol.14
, pp. 2381
-
-
Knoll, G.A.1
MacDonald, I.2
Khan, A.3
-
8
-
-
33750953529
-
Consequences of immunosuppression minimization following diagnosis of gastrointestinal complications in renal transplant
-
Schnitzler M.A., Hardinger K.L., Burroughs T.E., et al. Consequences of immunosuppression minimization following diagnosis of gastrointestinal complications in renal transplant. Am J Transplant 5 Suppl 11 (2005) 242
-
(2005)
Am J Transplant
, vol.5
, Issue.SUPPL. 11
, pp. 242
-
-
Schnitzler, M.A.1
Hardinger, K.L.2
Burroughs, T.E.3
-
9
-
-
15844416494
-
Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil
-
Arns W., Breuer S., Choudhury S., et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 19 (2005) 199
-
(2005)
Clin Transplant
, vol.19
, pp. 199
-
-
Arns, W.1
Breuer, S.2
Choudhury, S.3
-
10
-
-
3042772994
-
Review of the immunosuppressant enteric-coated mycophenolate sodium
-
Budde K., Glander P., Diekmann F., et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 5 (2004) 1333
-
(2004)
Expert Opin Pharmacother
, vol.5
, pp. 1333
-
-
Budde, K.1
Glander, P.2
Diekmann, F.3
-
11
-
-
1342346699
-
Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients
-
ERL B301 Study Group
-
Salvadori M., Holzer H., de Mattos A., et al., ERL B301 Study Group. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 4 (2004) 231
-
(2004)
Am J Transplant
, vol.4
, pp. 231
-
-
Salvadori, M.1
Holzer, H.2
de Mattos, A.3
-
12
-
-
33747104149
-
Long-term administration of enteric-coated mycophenolate sodium (EC-MPS, myfortic®) is safe in kidney transplant patients
-
Salvadori M., Holzer H., Civati G., et al. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS, myfortic®) is safe in kidney transplant patients. Clin Nephrol 66 (2006) 112
-
(2006)
Clin Nephrol
, vol.66
, pp. 112
-
-
Salvadori, M.1
Holzer, H.2
Civati, G.3
-
13
-
-
1342325540
-
Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study
-
ERL B302 Study Group
-
Budde K., Curtis J., Knoll G., et al., ERL B302 Study Group. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 4 (2004) 237
-
(2004)
Am J Transplant
, vol.4
, pp. 237
-
-
Budde, K.1
Curtis, J.2
Knoll, G.3
-
14
-
-
33747119649
-
Long-term safety and efficacy after conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS, myfortic®)
-
Budde K., Knoll G., Curtis J., et al. Long-term safety and efficacy after conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS, myfortic®). Clin Nephrol 66 (2006) 103
-
(2006)
Clin Nephrol
, vol.66
, pp. 103
-
-
Budde, K.1
Knoll, G.2
Curtis, J.3
-
15
-
-
4444331622
-
Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: interim results of a multicenter Latin American study
-
Myproms Latam Study Group
-
Abbud-Filho M., Girón F., Hernández E., et al., Myproms Latam Study Group. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: interim results of a multicenter Latin American study. Transplant Proc 36 (2004) 1647
-
(2004)
Transplant Proc
, vol.36
, pp. 1647
-
-
Abbud-Filho, M.1
Girón, F.2
Hernández, E.3
-
16
-
-
33744494308
-
Patient-reported gastrointestinal symptom burden and health-related quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium
-
Chan L.K., Mulgaonkar S., Walker S., et al. Patient-reported gastrointestinal symptom burden and health-related quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 81 (2006) 1290
-
(2006)
Transplantation
, vol.81
, pp. 1290
-
-
Chan, L.K.1
Mulgaonkar, S.2
Walker, S.3
-
17
-
-
0016916438
-
Prediction of creatinine clearance from serum creatinine
-
Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31
-
(1976)
Nephron
, vol.16
, pp. 31
-
-
Cockcroft, D.W.1
Gault, M.H.2
|